A New Risk Prediction Model for Detecting Endoscopic Activity of Ulcerative Colitis

키워드

참고문헌 (48)

1. Ng SC, "Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century : a systematic review of population-based studies", Lancet, 390, pp.2769~2778 (2017)
2. Ungaro R, "Ulcerative colitis", Lancet, 389, pp.1756~1770 (2017)
3. Kucharzik T, "Ulcerative colitis : diagnostic and therapeutic algorithms", Dtsch Arztebl Int, 117, pp.564~574 (2020)
4. Faubion WA Jr, "The natural history of corticosteroid therapy for inflammatory bowel disease : a population-based study", Gastroenterology, 121, pp.255~260 (2001)
5. Herrlinger KR, "Prioritization in inflammatory bowel disease therapy", Expert Rev Gastroenterol Hepatol, 17, pp.753~767 (2023)
6. D’Haens G, "A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis", Gastroenterology, 132, pp.763~786 (2007)
7. Peyrin-Biroulet L, "Selecting Therapeutic Targets in Inflammatory Bowel Disease(STRIDE) : Determining Therapeutic Goals for Treat-to-Target", Am J Gastroenterol, 110, pp.1324~1338 (2015)
8. Neurath MF, "Mucosal healing in inflammatory bowel diseases : a systematic review", Gut, 61, pp.1619~1635 (2012)
9. Frøslie KF, "Mucosal healing in inflammatory bowel disease : results from a Norwegian population-based cohort", Gastroenterology, 133, pp.412~422 (2007)
10. Lichtenstein GR, "Importance of mucosal healing in ulcerative colitis", Inflamm Bowel Dis, 16, pp.338~346 (2010)
11. Li X, "Risk prediction model based on blood biomarkers for predicting moderate to severe endoscopic activity in patients with ulcerative colitis", Front Med(Lausanne), 10, pp.1101237~ (2023)
12. Kim SY, "Adverse events related to colonoscopy : global trends and future challenges", World J Gastroenterol, 25, pp.190~204 (2019)
13. Mohammed Vashist N, "Endoscopic scoring indices for evaluation of disease activity in ulcerative colitis", Cochrane Database Syst Rev, 1, pp.CD011450~ (2018)
14. Lobatón T, "A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis", Inflamm Bowel Dis, 19, pp.1034~1042 (2013)
15. Nielsen OH, "Established and emerging biological activity markers of inflammatory bowel disease", Am J Gastroenterol, 95, pp.359~367 (2000)
16. Danese S, "Platelets in inflammatory bowel disease : clinical, pathogenic, and therapeutic implications", Am J Gastroenterol, 99, pp.938~945 (2004)
17. Blanck S, "Vitamin d deficiency is associated with ulcerative colitis disease activity", Dig Dis Sci, 58, pp.1698~1702 (2013)
18. Abraham BP, "Fecal markers : calprotectin and lactoferrin", Gastroenterol Clin North Am, 41, pp.483~495 (2012)
19. Burakoff R, "Blood-based biomarkers used to predict disease activity in Crohn’s disease and ulcerative colitis", Inflamm Bowel Dis, 21, pp.1132~1140 (2015)
20. Mak LY, "Combined use of common fecal and blood markers for detection of endoscopically active inflammatory bowel disease", Clin Transl Gastroenterol, 11, pp.e00138~ (2020)
21. Iasonos A, "How to build and interpret a nomogram for cancer prognosis", J Clin Oncol, 26, pp.1364~1370 (2008)
22. Magro F, "Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1 : definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders", J Crohns Colitis, 11, pp.649~670 (2017)
23. Schroeder KW, "Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis : a randomized study", N Engl J Med, 317, pp.1625~1629 (1987)
24. Satsangi J, "The Montreal classification of inflammatory bowel disease : controversies, consensus, and implications", Gut, 55, pp.749~753 (2006)
25. GBD 2017 Inflammatory Bowel Disease Collaborators, "The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet Gastroenterol Hepatol, 5, pp.17~30 (2020)
26. Dignass A, "Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2 : current management", J Crohns Colitis, 6, pp.991~1030 (2012)
27. Chen YH, "The relationship between C-reactive protein", albumin ratio and disease activity in patients with inflammatory bowel disease, 2020, pp.2020, 3467419~
28. Descos L, "Serum levels of beta-2-microglobulin : a new marker of activity in Crohn’s disease", N Engl J Med, 301, pp.440~441 (1979)
29. Zissis M, "B2 microglobulin : is it a reliable marker of activity in inflammatory bowel disease?", Am J Gastroenterol, 96, pp.2177~2183 (2001)
30. Yamamoto-Furusho JK, "Serum levels of beta2 microglobulin and ultrasensitive C-reactive protein as markers of histological activity in ulcerative colitis", Gac Med Mex, 146, pp.31~35 (2010)
31. Bai X, "Changes in MMP-2, MMP-9, inflammation, blood coagulation and intestinal mucosal permeability in patients with active ulcerative colitis", Exp Ther Med, 20, pp.269~274 (2020)
32. Shen J, "Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease : a gender-stratified, cohort analysis", Thromb Res, 123, pp.604~611 (2009)
33. Kume K, "Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis", Intern Med, 46, pp.1323~1329 (2007)
34. Stadnicki A, "Selected risk factors of thrombotic complications in patients with ulcerative colitis", Wiad Lek, 56, pp.341~347 (2003)
35. Danese S, "Inflammation and coagulation in inflammatory bowel disease : the clot thickens", Am J Gastroenterol, 102, pp.174~186 (2007)
36. Lu PP, "Pro-inflammatory effect of fibrinogen and FDP on vascular smooth muscle cells by IL-6, TNF-α and iNOS", Life Sci, 88, pp.839~845 (2011)
37. Stadnicki A, "Involvement of coagulation and hemostasis in inflammatory bowel diseases", Curr Vasc Pharmacol, 10, pp.659~669 (2012)
38. Linskens RK, "Predictive value of inflammatory and coagulation parameters in the course of severe ulcerative colitis", Dig Dis Sci, 46, pp.644~648 (2001)
39. Kumar S, "Severe ulcerative colitis : prospective study of parameters determining outcome", J Gastroenterol Hepatol, 19, pp.1247~1252 (2004)
40. Kjeldsen J, "Assessment of disease severity and activity in inflammatory bowel disease", Scand J Gastroenterol, 28, pp.1~9 (1993)
41. Tibble JA, "Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease", Gastroenterology, 123, pp.450~460 (2002)
42. van Rheenen PF, "Faecal calprotectin for screening of patients with suspected inflammatory bowel disease : diagnostic meta-analysis", BMJ, 341, pp.c3369~ (2010)
43. Ishida N, "Effect of ulcerative colitis duration on the usefulness of immunochemical fecal occult blood test result as a disease activity biomarker", Int J Colorectal Dis, 35, pp.1729~1739 (2020)
44. Takashima S, "Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test", Am J Gastroenterol, 110, pp.873~880 (2015)
45. Lee MW, "Use of fecal occult blood testing as a diagnostic tool for clinical indications : a systematic review and meta-analysis", Am J Gastroenterol, 115, pp.662~670 (2020)
46. Song CS, "Association between red cell distribution width and disease activity in patients with inflammatory bowel disease", Dig Dis Sci, 57, pp.1033~1038 (2012)
47. Patel A, "Fecal calprotectin levels predict histological healing in ulcerative colitis", Inflamm Bowel Dis, 23, pp.1600~1604 (2017)
48. Nakarai A, "An elevated platelet count increases the risk of relapse in ulcerative colitis patients with mucosal healing", Gut Liver, 12, pp.420~425 (2018)

관련 논문AI추천